IMMX (Immix Biopharma) Quick Liquidity
The price action for Immix Biopharma, Inc. (IMMX) visualized on the GURU.Markets platform is currently at 24.63. The business focuses on developing immune-based cancer therapies, although success depends on the safety of new methods and the funding of research and development. Global conflicts could hinder international trials and the supply of components. Currently, the company aims to rapidly expand trials of modified cells to combat cancer.
Immix Biopharma, Inc. (IMMX) - metric breakdowns and financial figures
To stress-test assets, an investor must evaluate a business's ability to instantaneously settle short-term debts, excluding illiquid inventories from the calculation. Since Immix Biopharma, Inc. (IMMX) focuses on CAR-T asset clinical trials through partnerships with medical centers, the quick liquidity on the chart reflects the actual reserve of cash and accounts receivable required to sustain operations without external support.